Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

In a murine relapsing experimental allergic encephalomyelitis (EAE) model, gene therapy to block TNF was investigated with the use of a retroviral dimeric p75 TNF receptor (dTNFR) construct. To effectively produce these TNF inhibitors in vivo, a conditionally immortalized syngeneic fibroblast line was established, using a temperature-sensitive SV40 large T Ag-expressing retrovirus. These cells were subsequently infected with a retrovirus expressing soluble dTNFR. CNS-injected cells could be detected 3 mo after transplantation and were shown to produce the transgene product by immunocytochemistry and ELISA of tissue fluids. These levels of dTNFR protein were biologically active and could significantly ameliorate both acute and relapsing EAE. This cell-based gene-vector approach is ideal for delivering proteins to the CNS and has particular relevance to the control of inflammatory CNS disease.

Original publication

DOI

10.4049/jimmunol.164.5.2776

Type

Journal article

Journal

Journal of immunology (Baltimore, Md. : 1950)

Publication Date

03/2000

Volume

164

Pages

2776 - 2781

Addresses

Neuroinflammation Group, Institute of Neurology, and Department of Clinical Science, Institute of Ophthalmology, University College London, United Kingdom.

Keywords

Kidney, Cell Line, Transformed, Fibroblasts, Animals, Humans, Mice, Encephalomyelitis, Autoimmune, Experimental, Acute Disease, Chronic Disease, Recurrence, Receptors, Tumor Necrosis Factor, Receptors, Tumor Necrosis Factor, Type II, Antigens, CD, Brain Tissue Transplantation, Injections, Intraventricular, Dimerization, Genetic Vectors, Solubility, Genetic Therapy